Drug Sponsors

Boston Scientific to acquire C.R. Bard’s electrophysiology business

Tuesday, July 2, 2013 01:11 PM

Boston Scientific, a global medical technology company, will acquire Bard, the electrophysiology (EP) business of C.R. Bard, for $275 million in cash.

More... »

Johnson & Johnson opens Boston Innovation Center

Friday, June 28, 2013 02:12 PM

Johnson & Johnson have announced the opening of the Johnson & Johnson Innovation Center in Boston. As part of Johnson & Johnson Innovation, the goal of the Boston Innovation Center is to advance healthcare by catalyzing collaborations in science and technology between regional innovators and the Johnson & Johnson family of companies across a diverse spectrum of early-stage opportunities.

More... »

Isotechnika Pharma receives funding from NRC-IRAP

Thursday, June 27, 2013 02:00 PM

Biopharmaceutical Isotechnika Pharma has received additional funding from the Canadian National Research Council Industrial Research Assistance Program ("NRC-IRAP") for its Non-Immunosuppressive Cyclophilin Antagonist Molecules ("NICAMs") program. NRC-IRAP helped network the NICAM program with global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including evaluation of anti-hepatitis C virus ("HCV") activity.

More... »

Biotech salaries in San Francisco Bay area lead nation

Wednesday, June 26, 2013 02:42 PM

Denver-based BioSpace, a source for biotech and life sciences news and recruitment, has released its inaugural Bay Area Hiring and Salary Report showing that the San Francisco area leads four of the nation's biotechnology regions in average salary.

More... »

AmVac receives two E.U. grants for development of novel vaccines

Tuesday, June 25, 2013 09:37 AM

Biopharmaceutical AmVac has announced that the E.U. approved two grant applications under the seventh framework program (FP7) for the development of vaccines against flu and leishmaniasis. The projects are joint initiatives of AmVac, other European companies and research institutes with expertise in vaccine design and development. Total funding for all participating partners is approximately $7.8 million and $7.2 million, respectively, over five years. Within the funding periods, both vaccines are expected to complete phase I clinical trials.

More... »

Lundbeck to simplify commercial structure

Friday, June 21, 2013 01:30 PM

Global pharmaceutical Lundbeck has plans to optimize its commercial structure in order to launch new medicines, through increased alignment across countries and improved competencies and investments in areas such as market access.   

More... »

AOP Orphan spins off 80% stake in Activartis, outlines business strategy

Wednesday, June 19, 2013 01:54 PM

AOP Orphan Pharmaceuticals will spin off its 80% stake in Activartis, a Vienna-based biotech with a platform for immune-based cancer vaccines, to a group of private investors.

More... »

Royalty Pharma’s offer lapses, withdraws judicial review

Wednesday, June 19, 2013 01:38 PM

Royalty Pharma has withdrawn its request for a judicial review of the Irish Takeover Panel's decision that required it to lapse its offer for Elan once shareholders approved its Share Repurchase Program at a special shareholders’ meeting Monday. Shareholders approved a $200 million share buyback.

More... »

Imprimis Pharmaceuticals acquires Buderer intellectual property assets

Tuesday, June 18, 2013 10:56 AM

Imprimis Pharmaceuticals has acquired the intellectual property (IP) rights related to proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug, a compounding pharmacy member of PCCA.

More... »

Elan shareholders approve one of four transactions

Monday, June 17, 2013 03:30 PM

Elan shareholders approved one of four transactions up for a vote at its special meeting Monday. Shareholders rejected plans for a $1 billion cash acquisition of a 21% stake in Theravance’s royalties from the respiratory franchise it shares with GSK; acquisition of Vienna, Austria-based AOP Pharmaceuticals for $348.8 million; and the spinout of ELND005 into a new Irish startup Speranza Therapeutics, with $70 million in funding.

More... »